StockNews.com Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX)

Stock analysts at StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Shares of NASDAQ AGRX opened at $1.51 on Thursday. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $2.63. The firm has a fifty day moving average of $1.48 and a 200-day moving average of $0.88. The stock has a market capitalization of $10.35 million, a PE ratio of -0.41 and a beta of 1.58.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter. The company had revenue of $5.58 million for the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC boosted its position in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.